Abstract Body

Background: We previously reported that HIV replication increases non-hepatocyte dependent procoagulant factors and decreases hepatocyte-dependent pro- and anticoagulant factors, resulting in a procoagulant state. Here we explore mortality risk associated with these changes in the context of treated HIV disease. Methodology: In a nested case-control study of the SMART and ESPRIT control arms (randomized to continuous antiretroviral therapy), we evaluated allcause mortality associations with 9 extrinsic pathway factors (listed in Table); 6 are hepatocyte products (FII, FVII, FIX, FX, antithrombin, protein C). Three controls were matched per case on enrollment date, age (+/- 5yrs), study, and country. Odds ratios (OR) with 95% confidence intervals (CI) for 4th vs. 1st quartile of each marker were estimated using conditional logistic regression accounting for matching factors and adjusting for gender and race. To study the combined effect of the hepatocyte-dependent factors, individual biomarkers for each case/control set were ranked and combined over the 6 biomarkers to obtain a “Hepatocyte Score”. Additional covariates studied included: hepatitis co-infection, diabetes, cardiovascular disease, and baseline CD4, HIV RNA, and IL-6. Results: Among cases (n=134) and controls (n=388), respectively, median CD4 count was 454 and 495 cells/mm3, and 65 and 77% had viral suppression at baseline. Median factor (F) levels and mortality OR are listed (Table); findings include: 1) mortality increased with higher FV and FVIII levels (non-hepatocyte procoagulant cofactors), 2) mortality was inversely related to FVII levels, protein C (anticoagulant), as well as the composite hepatocyte score; mortality association for the score was not attenuated after adjustment for all covariates (OR 0.38; p=0.01), 3) When restricted to participants with viral suppression at entry, FV (OR 1.97; p=0.05), FVIII (OR 2.28, p=0.03), FVII (OR 0.35, p<0.01) and protein C (OR 0.38, p=0.02) remained associated with mortality 4) Adjusting specifically for IL-6 levels attenuated FV and FVIII, but not FVII or Protein C, associations. Conclusions: Findings support that hypercoagulation contributes to disease risk via alterations in the profile of extrinsic pathway coagulation factors, mediated by inflammation (e.g., FVIII) and hepatocyte dysfunction (e.g., protein C). Studies are needed to further clarify mechanisms by which alterations in coagulation biology leads to disease among treated HIV patients.